HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Previous close
$1.17
Day range
$1.14 - $1.18
Year range
$0.97 - $9.79
Market cap
12.44M USD
Avg Volume
6.00M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.32M | 39.96% |
Net income | -2.39M | -56.96% |
Net profit margin | — | — |
Earnings per share | -0.44 | — |
EBITDA | -2.50M | -57.51% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 10.70M | 98.61% |
Total assets | 11.50M | 96.16% |
Total liabilities | 1.67M | 81.28% |
Total equity | 9.84M | — |
Shares outstanding | 10.76M | — |
Price to book | 0.69 | — |
Return on assets | -54.92% | — |
Return on capital | -62.83% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -2.39M | -56.96% |
Cash from operations | -2.08M | -6.76% |
Cash from investing | -7.00K | — |
Cash from financing | 2.02M | -23.55% |
Net change in cash | -70.00K | -110.12% |
Free cash flow | -1.27M | 11.16% |
About
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Founded
2011
Website
Employees
5
